Health News

At the Medicap Pharmacy® stores, we are dedicated to providing products and services to care for your family’s wellness. One of those services is health news you can trust. Use the filters to focus on the information that is important to you, then bookmark this page to make it a regular stop anytime you’re online.


FDA Approved Treatment Option - Non Small Cell Lung Cancer
An Approved Treatment Option For Previously Treated Advanced NSCLC. Learn More.
Lung Cancer Rx Receives FDA Approval
A lung cancer drug has received regular approval from the US Food and Drug Administration (FDA).
Tecentriq Gets a New Job
The US Food and Drug Administration has approved Tecentriq (atezolizumab) to treat advanced lung cancer.
A New Job for Xalkori
The US Food and Drug Administration (FDA) approved Xalkori (crizotinib) to treat patients with advanced non-small cell lung cancer (NSCLC) who have tumors with an ROS-1 gene alteration.
A New Option for ALK-Positive Lung Cancer
The U.S. Food and Drug Administration today approved Alecensa (alectinib) to treat people with advanced (metastatic) ALK-positive non-small cell lung cancer (NSCLC) whose disease has worsened after, or who could not tolerate treatment with, another therapy called Xalkori (crizotinib).
FDA OKs Lung Cancer Rx Portrazza
The U.S. Food and Drug Administration today approved Portrazza (necitumumab) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancer.
FDA Approves New Lung Cancer Rx
On November 13, 2015, the U. S. Food and Drug Administration granted accelerated approval to osimertinib (TAGRISSO) once daily tablets, AstraZeneca Pharmaceuticals LP, for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.
FDA Expands Opdivo Approval
The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy.
Melanoma Rx May Treat Lung Cancer, Too
Turns out a melanoma medication could also help patients with a different type of cancer.
Advanced Non-Small Cell Lung Cancer Rx Approved
The U.S. Food and Drug Administration today granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1. Keytruda is approved for use with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, the first test designed to detect PD-L1 expression in non-small cell lung tumors.